FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea

The FDA approved two oral formulations of the Pfizer (NYSE: PFE) drug tafamidis, to be sold as Vyndaqel and Vyndamax. The drug has been approved specifically to treat the potentially deadly heart problems faced by patients with both the hereditary and “wild-type” forms of ATTR, the latter of which develops over time.